Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Location status: Recruiting
NCT Number: NCT05610852
This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.
Interested in participating?
Request Info19 year and older
Male
Interventional
Not applicable
Cleveland, Ohio, 44195, United States
Location status: Recruiting
The primary objective is to evaluate the in-field recurrence rates and recurrence free survival - defined as the absence of clinically significant prostate cancer within the treated zone (identified by prostate MRI and subsequent targeted prostate biopsy).
Secondary objectives of interest are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.
Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.
Time frame: 1 year after treatment
Number of patients with absence of clinically significant prostate cancer on prostate MRI and targeted prostate biopsy
Time frame: 2 years after treatment
Number of patients with absence of clinically significant prostate cancer on prostate MRI and targeted prostate biopsy
Time frame: 3 years after treatment
Number of patients with absence of clinically significant prostate cancer on prostate MRI and targeted prostate biopsy
Time frame: At initial treatment (postoperative day 0)
Minutes from incision to closing during surgery (median)
Time frame: Within 3 months after treatment.
Clavien-dindo classification number (1-5), number (percent)
Time frame: Once at first follow up (up to 7 days after initial treatment)
Units of oral morphine equivalent dosing (mg), median
Time frame: Up to 1 day after initial treatment
Time that patient is observed in the hospital after surgery, in hours (median)
Time frame: Up to 7 days after initial treatment
Time at which the foley catheter is removed after treatment, in days (median)
Time frame: Assessed at each visit for up to 1 year after treatment
Time at which the patient becomes continent in days (median)
Time frame: Assessed at each visit for up to 1 year after treatment
Continence defined as using 1 pad for security or less for stress urinary incontince, recorded as yes or no (percent)
Time frame: Assessed at each visit for up to 3 years
Assessed using scores from a validated survey (IIEF-5). Recorded as the the score from 5 (impotent) to 25 (no impotence), median.
Time frame: Assessed at each visit for up to 3 years
PSA recurrence defined as PSA nadir after treatment +1ng/ml within 12 months or PSA Nadir + 1.5ng/ml from 12-36 months. Recorded as yes or no (percent)
Time frame: Assessed at the time of clinic visits up to 3 years after treatment.
Time point at which the patient undergoes treatment for prostate cancer recurrence
Contact information is provided by the study sponsor or research team.
Case Comprehensive Cancer Center
Other
Prospective Single-Center Randomized Study Of Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound (HIFU)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05751434
Genital Diseases, Genital Diseases, Male
Los Angeles, California, United States
View Trial DetailsNCT06957691
Adenocarcinoma, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT05616650
Genital Diseases, Genital Diseases, Male
Bethesda, Maryland, United States
View Trial DetailsNCT07635238
Genital Diseases, Genital Diseases, Male
Basking Ridge, New Jersey, United States
View Trial Details